Wuschek, Alexander
Bussas, Matthias
El Husseini, Malek
Harabacz, Laura
Pineker, Viktor
Pongratz, Viola
Berthele, Achim
Riederer, Isabelle
Zimmer, Claus
Hemmer, Bernhard
Kirschke, Jan S.
Mühlau, Mark http://orcid.org/0000-0002-9545-2709
Funding for this research was provided by:
Bayerisches Staatsministerium für Wissenschaft und Kunst (F.4-V0134.K5.1/86/34, F.4-V0134.K5.1/86/34)
Faculty of Medicine, Munich University of Technology (KKF 2020)
Technische Universität München
Article History
Received: 31 May 2022
Revised: 26 September 2022
Accepted: 27 September 2022
First Online: 7 October 2022
Declarations
:
: The authors declare that they have no conflict of interest. Alexander Wuschek, Matthias Bussas, Malek El Husseini, Laura Harabacz, Viktor Pineker, Isabelle Riederer, and Claus Zimmer have nothing to disclose. Viola Pongratz received research funding from Novartis (Oppenheim Förderpreis 2017). Jan S. Kirschke has received research funding from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; project 432290010), the German Federal Ministry of Education and Research (13GW0469D) and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (101045128—iBack-epic—ERC-2021-COG). He is Co-Founder of Bonescreen GmbH. Achim Berthele has received consulting and/or speaker fees from Alexion, Bayer Healthcare, Biogen, Celgene, Novartis, Roche and Sandoz/Hexal. His institution has received compensation for clinical trials from Alexion, Biogen, Merck, Novartis, Roche, and Sanofi Genzyme. Bernhard Hemmer is associated with DIFUTURE (Data Integration for Future Medicine) [BMBF 01ZZ1804[A-I]]. Bernhard Hemmer received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology [EXC 2145 SyNergy—ID 390857198] and the European Union’s Horizon 2020 Research and Innovation Program [grant MultipleMS, EU RIA 733161]. He has served on scientific advisory boards for Novartis; he has served as DMSC member for AllergyCare, Sandoz, Polpharma and TG therapeutics; he or his institution have received speaker honoraria from Desitin; his institution received research grants from Regeneron for multiple sclerosis research. He holds part of two patents; one for the detection of antibodies against KIR4.1 in a subpopulation of patients with multiple sclerosis and one for genetic determinants of neutralizing antibodies to interferon. Mark Mühlau received research support from the Bavarian State Ministry for Science and Art (Collaborative Bilateral Research Program Bavaria—Québec: AI in medicine, Grant F.4-V0134.K5.1/86/34), the German Research Foundation (DFG SPP2177; Radiomics: Next Generation of Biomedical Imaging; project number 428223038); the National Institutes of Health (Grant 1R01NS112161-01); the German Federal Ministry of Education and Research (DIFUTURE: 01ZZ1603[A-D] and 01ZZ1804[A-I]).